Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Ability to augment glucose uptake ("substrate flexibility"), defined as change in rate of glucose uptake from rest to exercise
研究概览
简要总结
Pulmonary arterial hypertension(PAH) is associated with the development of right heart failure. In the setting of heart failure, the heart shifts to increasing dependence on glucose metabolism. In this study, the investigators will perform cardiac positron emission tomography/magnetic resonance imaging (PET/MRI) scans to measure glucose metabolism in the heart before and after initiation of pulmonary vasodilator therapy for pulmonary arterial hypertension.
详细描述
Pulmonary arterial hypertension is associated with the development of right heart failure. In the setting of heart failure, the heart shifts to increasing dependence on glucose metabolism. In this study, the investigators will perform cardiac positron emission tomography/magnetic resonance imaging (PET/MRI) scans to measure glucose metabolism in the heart before and after initiation of pulmonary vasodilator therapy for pulmonary arterial hypertension. By utilizing a rest-exercise protocol and continuous PET imaging acquisition, we can capture real-time changes in glucose uptake in the heart in response to acute exercise. By coupling these measures of dynamic glucose utilization with MRI-based cardiac function, we will determine cardiac metabolic efficiency.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •World Health Organization(WHO) group PAH secondary into idiopathic pulmonary arterial hypertension(IPAH) or connective tissue disease associated pulmonary arterial hypertension (CTDPAH)
- •New York Heart Association (NYHA) classification I - III heart failure
- •Vasodilator therapy naive
- •Able to provide informed consent
排除标准
- •Metabolic disorders such as uncontrolled diabetes (A1c > 8%) that may interfere with FDG uptake
- •Baseline 6-minute walk distance (6MWD) < 400 feet or NYHA class IV heart failure
- •Musculoskeletal abnormalities that would prevent exercise
- •Contraindications to MRI
结局指标
主要结局
Ability to augment glucose uptake ("substrate flexibility"), defined as change in rate of glucose uptake from rest to exercise
时间窗: 6 months
Substrate flexibility is defined as the change in myocardial to blood pool glucose uptake rate from rest to exercise.
次要结局
- Change in substrate flexibility after initiation of pulmonary vasodilator therapy(6 months)